The antibody recognizes the typical amyloid deposits in brains of patients suffering from the disease. This antibody has been developed against the carboxy terminal extracellular sequence of the mutated BRI protein.
ITM2B
Reaktivität: Human
ELISA
Wirt: Kaninchen
Polyclonal
Biotin
Applikationshinweise
Suitable for Immunohistochemistry on frozen sections. Suggested positive control: pathological brain sections. (Not recommended in Western blots). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg /ml
Buffer
PBS, pH 7.2, containing 0.09 % sodium azide as preservative.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody at 2-8 °C (Lyophilized) or reconstituted in small aliquots at -20 °C.
The mutated BRI protein (ITM2B) was identified in patients with familial British dementia. The unusual 277 residue precursor protein releases a 34-residue amyloidogenic peptide by the action of the protease furin, leading to the deposition of a protein fragment that seems to be involved in the pathogenesis of familial British dementia.Synonyms: BRI, BRI2, ITM2B, Integral membrane protein 2B, Transmembrane protein BRI